Affiliation:
1. Division of Basic and Translational Medicine, Department of Surgery, University of Minnesota, MN, United States
Abstract
Pancreatic cancer is an aggressive malignant disease and the efficacy of current treatments
for unresectable diseases is quite limited despite recent advances. Gene therapy /virotherapy
strategies may provide new options for the treatment of various cancers including pancreatic cancer.
Oncolytic adenovirus shows an antitumoral effect via its intratumoral amplification and strong cytocidal
effect in a variety of cancers and it has been employed for the development of potent oncolytic
virotherapy agents for pancreatic cancer. Our ultimate goal is to develop an oncolytic adenovirus
enabling the treatment of patients with advanced or spread diseases by systemic injection. Systemic
application of oncolytic therapy mandates more efficient and selective gene delivery and needs to
embody sufficient antitumor effect even with limited initial delivery to the tumor location. In this review,
the current status of oncolytic adenoviruses from the viewpoints of vector design and potential
strategies to overcome current obstacles for its clinical application will be described. We will also
discuss the efforts to improve the antitumor activity of oncolytic adenovirus, in in vivo animal models,
and the combination therapy of oncolytic adenovirus with radiation and chemotherapy.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献